KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

BioNTech SE (BNTX) Share-based Compensation (IS): 2021-2024

Historic Share-based Compensation (IS) for BioNTech SE (BNTX) over the last 4 years, with Dec 2024 value amounting to -$165.1 million.

  • BioNTech SE's Share-based Compensation (IS) rose 96.67% to -$4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$33.4 million, marking a year-over-year increase of 79.52%. This contributed to the annual value of -$165.1 million for FY2024, which is 79.97% up from last year.
  • As of FY2024, BioNTech SE's Share-based Compensation (IS) stood at -$165.1 million, which was up 79.97% from -$824.4 million recorded in FY2023.
  • BioNTech SE's Share-based Compensation (IS)'s 5-year high stood at -$15.3 million during FY2021, with a 5-year trough of -$824.4 million in FY2023.
  • For the 3-year period, BioNTech SE's Share-based Compensation (IS) averaged around -$347.4 million, with its median value being -$165.1 million (2024).
  • Per our database at Business Quant, BioNTech SE's Share-based Compensation (IS) slumped by 1,459.89% in 2023 and then soared by 79.97% in 2024.
  • BioNTech SE's Share-based Compensation (IS) (Yearly) stood at -$15.3 million in 2021, then slumped by 244.76% to -$52.8 million in 2022, then slumped by 1,459.89% to -$824.4 million in 2023, then surged by 79.97% to -$165.1 million in 2024.